Cullinan Therapeutics Inc’s filing revealed that its Chief Legal Officer SUMER JACQUELYN L unloaded Company’s shares for reported $33652.0 on Dec 18 ’25. In the deal valued at $9.67 per share,3,480 shares were sold. As a result of this transaction, SUMER JACQUELYN L now holds 135,432 shares worth roughly $1.31 million.
Then, Jones Jeffrey Alan sold 4,632 shares, generating $44,791 in total proceeds. Upon selling the shares at $9.67, the Chief Medical Officer now owns 169,532 shares.
Before that, Michaelson Jennifer sold 2,898 shares. Cullinan Therapeutics Inc shares valued at $28,024 were divested by the Chief Scientific Officer at a price of $9.67 per share. As a result of the transaction, Michaelson Jennifer now holds 133,980 shares, worth roughly $1.3 million.
UBS began covering CGEM with “Buy” recommendation on October 24, 2024. Stifel started covering the stock on May 01, 2024. It rated CGEM as “a Buy”.
Price Performance Review of CGEM
On Friday, Cullinan Therapeutics Inc [NASDAQ:CGEM] saw its stock fall -3.01% to $9.68. Over the last five days, the stock has lost -18.79%. Cullinan Therapeutics Inc shares have fallen nearly -15.75% since the year began. Nevertheless, the stocks have fallen -20.53% over the past one year. While a 52-week high of $13.33 was reached on 11/24/25, a 52-week low of $5.68 was recorded on 10/03/25.
Levels Of Support And Resistance For CGEM Stock
The 24-hour chart illustrates a support level at 9.48, which if violated will result in even more drops to 9.28. On the upside, there is a resistance level at 10.01. A further resistance level may holdings at 10.34.
How much short interest is there in Cullinan Therapeutics Inc?
A steep rise in short interest was recorded in Cullinan Therapeutics Inc stocks on 2025-11-28, growing by 0.37 million shares to a total of 6.88 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-31 was 6.51 million shares. There was a rise of 5.34%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on April 15, 2024 when William Blair began covering the stock and recommended ‘”an Outperform”‘ rating.
